M.Sc, PG degree in Biological Sciences, Qualified in National Level Examinations conducted by Central Government Departments and Agencies, CSIR-UGC NET, GATE, DBT-BET
Design and synthesis of small molecules for medicinal chemistry. Additionally, candidate should perform nucleic acid delivery and conduct preclinical animal experiments.
The candidates should mandatory have extensive experience through their PhD or other trainings in working with transplantable or inducible mouse models of cancer, and be well-versed in multi-colour flow cytometry. The candidates should be well-versed with regular laboratory techniques, which include but are not limited to western blotting, Immunohistochemistry, qPCR, etc
To carry out day-to-day lab research activities in the lab. Self-driven candidates interested in infectious disease research and with experience in parasitology, imaging, Molecular Biology, entomology and mosquito infection research are preferred.
Developing Repertoire of Orally Deliverable Phospholipid-Drug Conjugates for targeting Colorectal and Hepatocellular Carcinoma. MSc Biotechnology, Chemistry, Pharmacy, Pharmacology qualified with any National Level Test.
Candidates having research experiences in the area of renal diseases using Drosophila model, molecular biology, microscopy will be given preference. The initial appointment will be for one year and which may be extended depending upon the satisfactory performance of the candidate till the duration of the project.
Pharmacological targeting of Adiponectin receptor in obesity-associated decline in energy metabolism and insulin sensitivity – Application in diabetes management.
Research Associate, Research Staff will carry perform experimental work related to compositional analysis and process optimization of formulations. Additionally, he/she will operate and maintain analytical instruments such as HPLC, UV-Vis, FTIR, etc
A Prospective, Multicenter, Single-arm, Open-label, Phase IV, Post authorization Interventional Study to Assess the Safety and Efficacy of Asciminib in Indian Patients with Ph+ CML-CP without T315I Mutation, Previously Treated with two or more Tyrosine Kinase Inhibitors and Ph+ CML-CP with T315I Mutation